Search Results 411-420 of 18365 for alopecia

1. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors - Mayo Clinic

   - All grades of alopecia are acceptable; - Endocrine dysfunction on replacement therapy is acceptable. - Severe or unstable medical condition, including ...

2. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

3. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

   Received chemotherapy or radiotherapy within 3 weeks prior to randomization or those who have not recovered to =< grade 1 adverse events (other than alopecia) ...

4. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

   Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...

5. Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) - Mayo Clinic

   ... alopecia and the criteria outlined; Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas ...

6. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

   ... alopecia and neuropathy - Patients who are receiving any other investigational agents - History of allergic reactions attributed to compounds of similar ...

7. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Seborrheic dermatitis, Melasma, Vitiligo. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann ...

8. A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - Mayo Clinic

   * Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points ...

9. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer - Mayo Clinic

   ... alopecia and peripheral neuropathy =< grade 1 - Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as ...

10. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...